Co-morbidity between cardiovascular pathology and depression: Role of inflammation

Inflammation in Psychiatry

Volumn 28, Issue , 2013, Pages 144-161

  Halaris, Angelos ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925704719     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000343981     Document Type: Chapter

References (159)

1. Dahlof B: Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol 2010;105(1 suppl):3A-9A.
2. Lloyd-Jones DM, Hong Y, Labarthe D, et al: Defining and setting national goals for cardiovascular health promotion and disease reduction. Circulation 2010;121:586-613.
3. Waldman SA, Terzic A: Cardiovascular health: the global challenge. Clinical Pharmacol Ther 2011;90:483-485.
4. Terzic A, Waldman SA: Chronic diseases: the emerging pandemic. Clin Transl Sci 2011;4:225-226.
5. Kovasic JC, Fuster V: From treating complex coronary disease to promoting cardiovascular health: therapeutic transitions and challenges 2010-2020. Clin Pharmacol Ther 2011;90:509-518.
6. Viles-Gonzalez JF, Fuster V, Badimon JJ: Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004;25: 1197-1207.
7. American Heart Association: Heart Disease and Stroke Statistics-2004 Update. Dallas, American Heart Association, 2004.
8. Murray CJ, Lopez AD: Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-1442.
9. Demyttenaere K, Bruffaerts R, Posada-Villa J, et al: Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world Mental Health surveys. JAMA 2004;291:2581-2590.
10. Centers for Disease Control and Prevention (CDC): Current depression among adults-United states, 2006 and 2008. Morb Mortal Wkly Rep 2010;59: 1229-1235.
11. Lepin JP, Briley M: The increasing burden of depression. Neuropsych Dis Treat 2011;7(suppl 1):3-7.
12. Rozanski A, Blumenthal JA, Kaplan J: Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192-2217.
13. Barth J, Schumacher M, Herrmann-Lingen C: Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom. Med 2004;66:802-813.
14. Gump BB, Matthews KA, Eberly LE, Chang YF, MRFIT Research Group: Depressive symptoms and mortality in men: results from Multiple Risk Factor Intervention Trial. Stroke 2005;36: 98-102.
15. Halaris A: Co-morbidity between depression and cardiovascular disease. Int Angiol 2009;28:92-99.
16. Saleptsis VG, Lambropoulos N, Halaris A, Angelopoulos NV, Giannoukas AD: Depression and atherosclerosis. Int Angiol 2011;30:97-104.
17. Fielding R: Depression and acute myocardial infarction: a review and reinterpretation. Soc Sci Med 1991;32:1017-1027.
18. Schleifer SJ, Macari-Hinson MM, Coyle DA: The nature and course of depression following myocardial infarction. Arch Intern Med 1989;149:1785-1789.
19. Frasure-Smith N, Lesperance F, Talajic M: Depression following myocardial infarction: impact of 6-month survival. JAMA 1993;270:1819-1825.
20. Frasure-Smith N, Lesperance F, Talajic M: Depression and 18-month prognosis after myocardial infraction. Circulation 1995;91:999-1005.
21. Lesperance F, Frasure-Smith N, Jueau M, Theroux P: Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000;160:1354-1360.
22. Ahern DK, Gorkin L, Anderson JL, Tierney C, Hallstrom A, Ewart C, Capone RJ, Schron E, Kornfeld D, Herd JA, Richardson DW, Follick MJ: Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990;66:59-62.
23. Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, Fauerbach JA: Even minimal symptoms of depression increase mortality risk after acute myocardial infection. Am J Cardiol 2001;88:337-341.
24. Ford DE, Mead LA, Chang PP: Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med 1998;158:1422-1426.
25. Ariyo AA, Haan M, Tangen CM, Ruteledge JC, Cushman M, Dobs A: Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 2000;102:1773-1779.
26. Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT: Depression and cardiac mortality: Results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58:221-227.
27. Jiang W, Alexander J, Christopher E, Kuchibhatia M, Gaulden LH, Cuffe MS: Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161:1849-1856.
28. Lesperance J, Frasure-Smith N, Talajic M, Bourassa M: Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms in myocardial infarction. Circulation 2002;105:1049-1053.
29. Junger J, Schellberg D, Muller-Tasch T: Depression increasingly predicts mortality in the course of congestive heart failure. Eur J Heart Fail 2005;7:261-267.
30. Sherwood A, Blumenthal JA, Trivedi R, et al: Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 2007;167: 367-373.
31. Eaton WW, Fogel J, Armenian HK: The Consequences of Psychopathology in the Baltimore Epidemiologic Catchment Area Follow-up. Medical and Psychiatric Co-morbidity over the Lifespan. Washington, American Psychiatric Publishing, 2006, pp 21-38.
32. Wulsin LR, Evans JC, Vasan RS, Murabito JM, Kelly-Hayes M, Benjamin E: Depressive symptoms, coronary heart disease, and overall mortality in the Framingham Heart Study. Psychosomatic Medicine 2005;67:697-702.
33. Musselman DL, Evans DL, Nemeroff CB: The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998;55:580-592.
34. O'Connor CM, Gurbel PA, Serebruany VL: Depression in ischemic heart disease. Am Heart J 2000;140:63-69.
35. Carney RM, Jaffe AS: Treatment of depression following acute myocardial infarction. JAMA 2002;288:750-751.
36. Nicholson A, Kuper H, Hemingway H: Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006;27:2763-2774.
37. Celano CM, Mastromauro CA, Lenihan EC, Januzzi JL, Rollman BL, Huffman JC: Association of baseline anxiety with depression persistence at 6 months in patients with acute cardiac illness. Psychosom Med 2012;74:93-99.
38. Gomez-Caminero A, Blumentals WA, Russo LJ, Brown RR, Castilla-Puentes R: Does panic disorder increase the risk of coronary heart disease? A cohort study of a national managed care database. Psychosom Med 2005;67:688-691.
39. Eaker ED, Sullivan LM, Kelly-Hayes M, D'Agostino RB, Benjamin EJ: Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: The Framingham Offspring Study. Psychosom Med 2005;67:692-696.
40. Friedmann E, Thomas SA, Liu F: Relationship of depression, anxiety, and social isolation to chronic heart failure outpatient mortality. Am Heart J 2006;152:940.e1-e8.
41. Sherrer JF, Chrusciel T, Zeringue A, Garfield LD, Hauptman PJ, Lustman PJ, Freedland KE, Carney RM, Bucholz KK, Owen R, True WR: Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. Am Heart J 2010;159:772-779.
42. Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, Neria Y: Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients; a meta-analytic review. PLoS ONE 2012;7:e38915.
43. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ: Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006;48:1527-1537.
44. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, et al: Effects of treating depression and low perceived social support on clinical events after myocardial infarction. The Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA 2003;289:3106-3116.
45. Newman JD, Muntner P, Shimbo D, Davidson KW, Shaffer JA, Edmondson D: Post-traumatic stress disorder (PTSD) symptoms predict delay to hospital in patients with acute coronary syndrome. PLoS ONE 2011;6:e27640.
46. von Känel R, Begre S, Abbas CC, Saner H, Gander ML, Schmid JP: Inflammatory biomarkers in patients with posttraumatic stress disorder caused by myocardial infarction and the role of depressive symptoms. Neuroimmunomodulation 2010;17:39-46.
47. Spindler H, Pedersen S: Posttraumatic stress disorder in the wake of heart disease: prevalence, risk factors, and future research directions. Psychosom Medicine 2005;67:715-723.
48. Stansfeld SA, Fuhrer R, Shipley MJ, Marmot MG: Psychological distress as a risk factor for coronary heart disease in the Whitehall II Study. Int J Epidemiol 2002;31:248-255.
49. Rasul F, Stansfeld SA, Hart CL, Smith GD: Psychological distress, physical illness, and risk of coronary heart disease. J Epidemiol Community Health 2005;59: 140-145.
50. Molloy GJ, Stamatakis E, Randall G, Hamer M: Marital status, gender and cardiovascular mortality: behavioural, psychological distress and metabolic explanations. Soc Sci Med 2009;69: 223-228.
51. Russ TC, Stamatakis E, Hamer M, Starr JM, Kivimaki M, Batty GD: Association between psychological distress and mortality: individual participant pooled analysis of 10 prospective cohort studies. Br Med J 2012;345:e4933.
52. Denollet J, Schiffer AA, Spek V: A general propensity to psychological distress affects cardiovascular outcomes. Circulation 2010;3:546-557.
53. Shen BJ, Avivi YE, Todaro JF, Spiro A, Laurenceau JP, Ward KD, Niaura R: Anxiety characteristics independently and prospectively predict myocardial infarction in men. J Am Coll Cardiol 2008;51: 113-119.
54. Denollet J, Gidron Y, Vrints CJ, Conraads VM: Anger, suppressed anger, and risk of adverse events in patients with coronary artery disease. Am J Cardiol 2010; 105:1555-1560.
55. Myrtek M: Meta-analyses of prospective studies on coronary heart disease, Type A personality, and hostility. Int J Cardiol 2001;79:245-251.
56. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), ed 4. Washington, American Psychiatric Association, 2000.
57. Lee HB, Bienvenu JO, Cho SJ, Ramsey CM, Bandeen-Roche K, Eaton WW, Nestadt G: Personality disorders and traits as predictors of incident cardiovascular disease: findings from the 23-year follow-up of the Baltimore ECA Study. Psychosomatics 2010;41:289-296.
58. Denollet J, Vrints CJ, Conraads VM: Comparing type D personality and older age as correlates of tumor necrosis factor-α dysregulation in chronic heart failure. Brain Behav Immun 2008;22: 736-743.
59. Selye H: The Stress of Life. McGraw-Hill, New York, 1956.
60. McEwen BS: Protective and damaging effects of stress mediators. N Engl J Med 1998;338:171-179.
61. McEwen BS: Stress, adaptation, and disease allostasis and allostatic load. Ann NY Acad Sci 1998;840:33-44.
62. Thayer JF, Lane RD: The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007;74:224-242.
63. Otte C, Neylan TC, Pipkin SS, Browner WS, Whooley MA: Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 2005; 162:2139-2145.
64. Licht CMM, de Geus EJC, Zitman FG, Hoogendijk WJG, van Dyck R, Penninx BWJH: Association between major depressive disorder and heart rate variability in the Netherlands study of depression and anxiety (NESDA). Arch Gen Psychiat 2008;65912:1358-1367.
65. Porges SW: The polyvagal theory: phylogenetic substrates of a social nervous system. Int J Psychophysiol 2001;42: 123-146.
66. Porges SW: Cardiac vagal tone; a physiological index of stress. Neurosci Biobehav Rev 1995;19:225-233.
67. Porges SW: Emotion: an evolutionary by-product of the neural regulation of the autonomic nervous system. Ann NY Acad Sci 1997;807:62-77.
68. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M: Persistence of increased cardiovascular risk in patients with Cushing's disease after 5 years of successful cure. J Clin Endocrinol Metab 1999;84:2264-2272.
69. Tracey KJ: The inflammatory reflex. Nature 2002;420:853-859.
70. Blalock JE: Harnessing a neural-immune circuit to control inflammation and shock. J Exp Med 2002;195:F25-F28.
71. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458-461.
72. Borovikova LV, Ivanova S, Nardi D, Zhang M, Yang H, Ombrellino M, Tracey KJ: Auton Neurosci 2000;85:141-147.
73. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ: Nicotinic acetylcholine receptor α7 subunit is an essential regulation of inflammation. Nature 2003;421:384-388.
74. Pavlov VA, Tracey KJ: The cholinergic anti-inflammatory pathway. Brain Behav Immun 2005;19:493-499.
75. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340: 115-126.
76. Lind L: Circulating markers of inflammation and atherosclerosis. Atherosclerosis 2003;169:203-214.
77. Frasure-Smith N, Lespérance F, Irwin MR, Sauvé C, Lespérance J, Théroux P: Depression, C-reactive protein and twoyear major adverse cardiac events in men after acute coronary syndromes. Biol Psychiatry 2007;62:302-308.
78. Hansson G: Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
79. Seta Y, Shan K, Bozkurt B, et al: Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996;2:243-249.
80. Petersen JW, Felker M: Inflammatory biomarkers in heart failure. Congest Heart Fail 2006;12:324-328.
81. Maes M, Bosmans E, Suy E, Vandervorst C, DeJonckheere C, Raus J: Depressionrelated disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr Scand 1991; 84:379-386.
82. Maes M: Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:11-38.
83. Wichers M, Maes M: The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5:375-388.
84. Lee KM, Kim YK: The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Int Immunopharmacol 2006;6:1298-1304.
85. Koenig, W: Inflammation and coronary heart disease: an overview. Cardiol Rev 2001;9:31-35.
86. Mulvihill NT, Foley JB: Inflammation in acute coronary syndromes. Heart 2002;87:201-204.
87. Robbins M, Topol EJ: Inflammation in acute coronary syndromes. Cleve Clin J Med 2002;69(suppl 2):SII130-SII142.
88. Maes M, Bosmans E, Meltzer HY, Scharpe S, Suy E: Interleukin-1beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993;150:1189-1193.
89. Maes M, Van der Planken, Van Gastel A, Desnyder R: Blood coagulation and platelet aggression in major depression. J Affect Disord 1996;40:35-40.
90. Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J: Inflammation and coagulation factors on persons >65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 2002;89:419-424.
91. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S: Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001;158:1252-1257.
92. Connor TJ, Leonard BE: Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998;62:583-606.
93. Leonard BE: Brain cytokines and the psychopathology of depression; in Leonard BE (ed.): Antidepressants. Basel, Birkhauser, 2001, pp 109-120.
94. Castanon N, Leonard BE, Neveu PJ, Yirmiya R: Effects of antidepressants on cytokine production and actions. Brain Behav Immun 2002;16:569-574.
95. Leonard BE, Myint A: Inflammation and depression: is there a causal connection with dementia? Neutox Res 2006;10: 149-160.
96. von Känel R, Hepp U, Kraemer B, Traber R, Keel M, Mica L, Schnyder U: Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J Psychiatr Res 2006;41: 744-752.
97. Empana JP, Sykes DH, Luc G, Juhan-Vague I, Arveiler D, Ferrieres J, Amouyel P, Bingham A, Montaye M, Ruidavets JB, Haas B, Evans A, Jouven X, Ducimetiere P, Group PS: Contributions of depressive mood and circulating inflammatory markers to coronary heart disease in healthy European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2005; 111:2299-2305.
98. Anda R, Williamson D, Jones D, Macera C, Eaker E, Glassman A, Marks J: Depressed affect, hopelessness, and the risk of ischemic heart disease in a cohort of US adults. Epidemiology 1993;4:285-294.
99. Kamphuis MH, Kalmijn S, Tijhuis MA, Geerlings MI, Giampaoli S, Nissinen A, Grobbee DE, Kromhout D: Depressive symptoms as risk factor of cardiovascular mortality in older European men: the Finland, Italy and Netherlands Elderly (FINE) study. Eur J Cardiovasc Prev Rehabil 2006;13:199-206.
100. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW: Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996;94:3123-3129.
101. Di Iorio A, Ferrucci L, Sparvieri E, Cherubini A, Volpato S, Corsi A, Bonafè M, Franceschi C, Abate, Paganelli R: Serum IL-1beta levels in health and disease: a population-based study. 'The InCHIANTI study'. Cytokine 2003;22: 198-205.
102. Biasucci LM: CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper. Circulation 2004;110:e560-e567.
103. Maes M: Introduction to the special section. Int J Neuropsychopharmacol 2002;5:329-331.
104. Dantzer R: Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001;933:222-234.
105. Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L, Davenport T, Wakefield D, Hickie I, Lloyd A: Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol Med 2004;34:1289-1297.
106. Smith RS: The macrophage theory of depression. Med Hypotheses 1991;35: 298-306.
107. Ur E, White PD, Grossman A: Hypothesis: cytokines may be activated to cause depressive illness and chronic fatigue syndrome. Eur Arch Psychiatry Clin Neurosci 1992;241:317-322.
108. Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, Newman MF: Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305-315.
109. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000;22:370-379.
110. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M: Antiinflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol 2001;21:199-206.
111. Kubera M, Kenis G, Bosmans E, Kajta M, Basta-Kaim A, Scharpe S, Budziszewska B, Maes M: Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol 2004;4:185-192.
112. Kenis G, Maes M: Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 2002;5:401-412.
113. Himmerich H, Binder EB, Künzel HE, Schuld A, Lucae S, Uhr M, Pollmächer T, Holsboer F, Ising M: Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry 2006;60: 882-888.
114. Mayer B, Holmer SR, Hengstenberg C, Lieb W, Pfeifer M, Schunkert H: Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels. Int J Cardiol 2005;103:182-186.
115. Janssen DG, Caniato RN, Verster JC, Baune BT: A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol 2010;25:201-215.
116. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M: The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006;11:680-684.
117. Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JMC: Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 2000;98: 531-535.
118. Piletz JE, Halaris A, Iqbal O, et al: Proinflammatory biomarkers in depression: treatment with venlafaxine. World J Biol Psychiatry 2009;10:313-323.
119. Dinan TG: Inflammatory markers in depression. Curr Opin Psychiatry 2008; 22:32-36.
120. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflammation to sickness and depression: when the immune system subjugates the brain. Nat rev Neurosci 2008;9:46-56.
121. Leonard BE: The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 2010;6:205-212.
122. Yoshizumi M, Perella MA, Burnett JC, Lee ME: Circ Res 1991;73:205-209.
123. Tucci M, Quatraro C, Frassanito MA, Silvestris F: Deregulated expression of monocyte chemoattractant protein-1 (MCP-1) in arterial hypertension: role in endothelial inflammation and atheromasia. J Hypertens 2006;24:1307-1318.
124. Verma S, Buchanan MR, Anderson TJ: Endothelial function testing as a biomarker of vascular disease. Circulation 2003;108:2054-2059.
125. Rybakowski JK, Wykretowicz A, Heymann-Szlachcinska A, Wysocki H: Impairment of endothelial function in unipolar and bipolar depression. Biol Psychiatry 2006;60:889-891.
126. Broadley AJ, Korszun A, Jones CJ, Frenneaux MP: Arterial endothelial function is impaired in treated depression. Heart 2002;88:521-523.
127. Smitherman TC, Milam M, Woo J: Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol 1981;48:395-402.
128. Levine SP, Lindenfield J, Ellis JB: Increased plasma concentrations of platelet factor-4 in coronary artery disease. Circulation 1981;64:626-632.
129. Laghrissi-Thode F, Wagner WR, Pollock BG: Elevated platelet factor 4 and betathromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997;42:290-295.
130. Kuijpers PM, Haumulyak K, Strik JJ: Beta-thromboglobulin and platelet factor 4 levels in post-myocardial infarction patients with major depression. Psychiatry Res 2002;109:207-210.
131. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marzec U, Harker LA, Nemeroff CB: Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153: 1313-1317.
132. Musselman DL, Marzec UM, Manatunga A, Penna S, Reemsnyder A, Knight BT, Baron A, Hanson SR, Nemeroff CB: Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000;57: 875-882.
133. Nemeroff CB, Musselman DL: Are platelets the link between depression and ischemic heart disease? Am Heart J 2000;140(4 suppl):57-62.
134. Piletz JE, Zhu H, Madakasira S, Pazzaglia P, Lindsay Devane C, Goldman N, Halaris A: Elevated P-selectin on platelets in depression: response to bupropion. J Psychiatr Res 2000;34:397-404.
135. Halaris A, Piletz JE: Relevance of imidazoline receptors and agmatine to psychiatry. Ann NY Acad Sci 2003;1009:1-19.
136. Serebruany VL, Glassman AH, Malinin AI, Sane DC, Finkel MS, Krishnan R, Atar D, Lekht V, O'Connor CM: Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis 2003;14:563-567.
137. Serebruany VL, Glassman AH, Malinin AI, et al: Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003;108: 939-944.
138. Serebruany VL, Suckow RF, Cooper TB, et al: Relationship between release of platelet/endothelial biomarkers and plasma levels of sertraline and N-desmethylsertraline in acute coronary syndrome patients receiving SSRI treatment for depression. Am J Psychiatry 2005;162:1165-1170.
139. Basterzi AD, Aydemir C, Kisa C, Aksaray S, Tuzer V, Yazici K, Göka E: IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol 2005;20:473-476.
140. Ignarro LJ: Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002;53:503-551.
141. Halaris A, Piletz J: Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs 2007;21:885-900.
142. Mendelson SD: The current status of the platelet 5-HT (2A) receptor in depression. J Affect Disord 2000;57:13-24.
143. Hrdina PD, Bakish D, Chudzik J, Ravindran A, Lapierre YD: Serotonergic markers in platelets of patients with major depression: upregulation of 5-HT2 receptors. J Psychiatr Neurosci 1995;20: 11-19.
144. Neuger J, El Khoury A, Kjellman BF, Wahlund B, Aberg-Wistedt A, Stain-Malgren R: Platelet serotonin functions in untreated major depression. Psychiatry Res 1999;85:189-198.
145. Shimbo D, Child J, Davidson K, Geer E, Osende JI, Reddy S, Dronge A, Fuster V, Badimon JJ: Exaggerated serotoninmediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002;89: 331-333.
146. Whyte EM, Pollock BG, Wagner WR, Mulsant BH, Ferrell RE, Mazumdar S, Reynolds CF 3rd: Influence of serotonintransporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry 2001;158:2074-2076.
147. Palazzolo DL, Quadri SK: Interleukin-1 inhibits serotonin release from the hypothalamus in vitro. Life Sci 1992;51: 1797-1802.
148. Zhu CB, Blakely RD, Hewlett WA: The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006;31:2121-2131.
149. Christmas DM, Potokar JP, Davies SJC: A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase. Neurpsychiatr Dis Treat 2011;7:431-439.
150. Wichers M, Maes M: The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5:375-388.
151. Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch HWM, Leonard BE: Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007;89:143-151.
152. Myint AH, Kim YK: Cytokine-serotonin interaction through IDO; a neurodegeneration hypothesis of depression. Med Hypoth 2003;61:519-525.
153. Miller CL, Llenos IC, Dulay JR, Weis S: Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006;1073-1074:25-37.
154. Myint AM, Kim YK, Verkerk R, Park SH, Scharpe S, Steinbusch HW, Leonard BE: Tryptophan breakdown pathway in bipolar mania. J Affect Disord 2007;102:65-72.
155. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson C, Bigger JT, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-291.
156. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Markedian J, Harrison WM, Barton D, Mclvor M: Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) group. JAMA 2002;288:701-709.
157. Sauer WH, Berlin JA, Kimmel SE: Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001;104:1894-1898.
158. Taylor CB, Youngblood ME, Catellier D, et al: for the ENRICHD Investigators. Arch Gen Psychiatry 2005;62:792-798.
159. Berkman LF, Blumenthal J, Burg M, Carney RM, et al: Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003;289: 3106-3116.